Dr Hamid on the Investigation of Fianlimab With Cemiplimab in Advanced Melanoma
Source: OncLive, June 2023
Omid Hamid, MD, discusses the investigation of the LAG-3 inhibitor fianlimab in combination with cemiplimab in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, discusses the investigation of the LAG-3 inhibitor fianlimab (REGN3767) in combination with cemiplimab-rwlc (Libtayo) in patients with advanced melanoma who were naïve to anti–PD-1 agents in the advanced setting.
Data from a phase 1 trial (NCT03005782) presented at the 2023 ASCO Annual Meeting showed that across 3 cohorts of patients, including 1 that included those who received anti–PD-1 treatment in the neoadjuvant or adjuvant setting, the combination elicited an overall response rate of 61% (95% CI, 51%-71%). Notably, responses were observed across key subgroups, including patients with poor prognosis, such as those with high lactate dehydrogenase or liver/visceral metastases, Hamid says.